[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334972-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334972-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","computational-approach-for-the-development-of-ph-selective-pd-1pd-l1-signaling-pathway-inhibition-in-fight-with-cancer","Computational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer","","Immunotherapy targeting the PD-1/PD-L1 pathway is promising yet carries the risk of unwanted immune activation against healthy cells. This study proposes selective inhibition of PD-L1 within the acidic tumor microenvironment. In silico workflows combine virtual screening with molecular mechanics and molecular dynamics to evaluate about 10,000 natural compounds from MolPort. Two pH conditions (7.4 and 5.5) simulate healthy versus cancer states. MolPort-001-742-690 shows stronger affinity under acidic conditions and lower toxicity than BMS-202 and LP23. A 1000 ns simulation supports complex stability, suggesting pH-selective in silico discovery for more precise, lower-toxicity immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/computational-approach-for-the-development-of-ph-selective-pd-1pd-l1-signaling-pathway-inhibition-in-fight-with-cancer/334972/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/computational-approach-for-the-development-of-ph-selective-pd-1pd-l1-signaling-pathway-inhibition-in-fight-with-cancer/334972.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic goal of this study?","Question",{"text":63,"@type":64},"To develop pH-selective inhibitors that block the PD-1/PD-L1 signaling pathway in the acidic tumor microenvironment, aiming to improve immunotherapy precision and reduce unwanted effects on healthy cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the researchers model healthy versus cancer conditions?",{"text":68,"@type":64},"They run simulations under two pH conditions, pH 7.4 to represent healthy environments and pH 5.5 to represent the acidic conditions typical of tumors.",{"name":70,"@type":61,"acceptedAnswer":71},"Which computational methods are used to identify potential inhibitors?",{"text":72,"@type":64},"The study uses in silico techniques including virtual screening, molecular mechanics, and molecular dynamics simulations to evaluate approximately 10,000 natural compounds from the MolPort database.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334972,1790313556,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","cancers   \nArticle  \nComputational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer  \nRoderick C. McDowell 1, Jordhan D. Booth 2, Allyson McGowan 2, Wojciech Kolodziejczyk 1, Glake A. Hill 1, Santanu Banerjee 2, Manliang Feng 2 and Karina Kapusta 2, *  \nCitation: McDowell, R.C.; Booth, J.D.; McGowan, A.; Kolodziejczyk, W.; Hill, G.A.; Banerjee, S.; Feng, M.; Kapusta, K. Computational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer. Cancers 2024, 16, 2295. [https://](https://)[ ](https://)[doi.org/10.3390/cancers16132295](doi.org/10.3390/cancers16132295)  \nReceived: 16 May 2024  \nRevised: 10 June 2024  \nAccepted: 20 June 2024  \nPublished: 22 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Chemistry, Physics and Atmospheric Sciences, Jackson State University, Jackson, MS 39217, USA; [roderick.mcdowell@yahoo.com](roderick.mcdowell@yahoo.com) (R.C.M.); [kolodziejczyk.wojciech@gmail.com](kolodziejczyk.wojciech@gmail.com) (W.K.); [glakeh@icnanotox.org](glakeh@icnanotox.org) (G.A.H.)  \n2 Department of Chemistry and Physics, Tougaloo College, Tougaloo, MS 39174, USA; [jdbooth@student.tougaloo.edu](jdbooth@student.tougaloo.edu) (J.D.B.); [ajmcgowan@student.tougaloo.edu](ajmcgowan@student.tougaloo.edu) (A.M.); [sbanerjee@tougaloo.edu](sbanerjee@tougaloo.edu) (S.B.); [mfeng@tougaloo.edu](mfeng@tougaloo.edu) (M.F.)  \n* Correspondence: [kkapusta@tougaloo.edu](kkapusta@tougaloo.edu)  \nSimple Summary: Despite considerable progress in cancer research and treatment, cancer continues to be a major health challenge, often requiring invasive treatments with substantial side effects. Immuno-therapy, which targets the immune system’s PD-1/PD-L1 pathway, represents a promising alternative. This critical pathway allows cancer cells to avoid immune destruction by inhibiting T-cells. Our study employs computational techniques to develop inhibitors that block the PD-L1 pathway, specifically in the acidic environment of tumors. By analyzing around 10,000 natural compounds, we identified a potential pH-selective inhibitor that shows greater effectiveness in the acidic conditions typical of cancerous tissues. This research suggests a novel approach for experimental groups to explore, focusing on developing targeted, pH-dependent inhibitors that could mark a significant step in enhancing the precision and effectiveness of immunotherapy treatments, potentially revolutionizing cancer therapy.  \nAbstract: Immunotherapy, particularly targeting the PD-1/PD-L1 pathway, holds promise in cancer treatment by regulating the immune response and preventing cancer cells from evading immune destruction. Nonetheless, this approach poses a risk of unwanted immune system activation against healthy cells. To minimize this risk, our study proposes a strategy based on selective targeting of the PD-L1 pathway within the acidic microenvironment of tumors. We employed in silico methods, such as virtual screening, molecular mechanics, and molecular dynamics simulations, analyzing approximately 10,000 natural compounds from the MolPort database to find potential hits with the desired properties. The simulations were conducted under two pH conditions (pH = 7.4 and 5.5) to mimic the environments of healthy and cancerous cells. The compound MolPort-001-742-690 emerged as a promising pH-selective inhibitor, showing a significant affinity for PD-L1 in acidic conditions and lower toxicity compared to known inhibitors like BMS-202 and LP23 . A detailed 1000 ns molecular dynamics simulation confirmed the stability of the inhibitor-PD-L1 comple","cbCaisvryWcUvwMj","https://ap.wps.com/l/cbCaisvryWcUvwMj","pdf",12205672,"English","# 1. Introduction\n# 2. Methods\n## 2.1 Virtual screening and compound selection\n## 2.2 Molecular mechanics and molecular dynamics simulations\n# 3. Results\n## 3.1 pH-dependent binding and affinity\n## 3.2 1000 ns stability of the inhibitor–PD-L1 complex\n# 4. Discussion\n# 5. Conclusions","[{\"question\":\"What is the main therapeutic goal of this study?\",\"answer\":\"To develop pH-selective inhibitors that block the PD-1/PD-L1 signaling pathway in the acidic tumor microenvironment, aiming to improve immunotherapy precision and reduce unwanted effects on healthy cells.\"},{\"question\":\"How do the researchers model healthy versus cancer conditions?\",\"answer\":\"They run simulations under two pH conditions, pH 7.4 to represent healthy environments and pH 5.5 to represent the acidic conditions typical of tumors.\"},{\"question\":\"Which computational methods are used to identify potential inhibitors?\",\"answer\":\"The study uses in silico techniques including virtual screening, molecular mechanics, and molecular dynamics simulations to evaluate approximately 10,000 natural compounds from the MolPort database.\"}]","Computational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer | PDF",1790009067,48]